Hongene Biotech Corporation & ReciBioPharm Establish a Gene Editing Development Partnership

Hongene Biotech Corporation and ReciBioPharm have announced a strategic collaboration that will enhance gene editing drug manufacturing capabilities. Hongene, renowned for its expertise in the nucleic acid manufacturing field, has recently pioneered a novel proprietary technology for sgRNA synthesis. This technique significantly diminishes impurities common in conventional production methods, thereby elevating product quality. ReciBioPharm, with its state-of-the-art facilities near Boston, MA, is a provider of comprehensive CDMO services, including the integrated development, analytics, and GMP manufacturing of plasmid, mRNA, LNP, and sterile drug products. The company is also on the forefront of continuous manufacturing technology for mRNA-LNP products through its work with MIT and its grant from the FDA’s CBER office to provide faster readiness and reaction to new pandemic threats.

The strategic alliance between the two companies creates a unique solution for innovators in the gene editing field. ReciBioPharm will expand its service portfolio to include sgRNA manufacturing, utilizing Hongene’s innovative synthesis process, providing plasmid, mRNA, sgRNA, LNP, and fill-finish services in a single facility. This will streamline the entire development and manufacturing process, mitigating the logistical complexities of dealing with multiple CDMOs, and ultimately accelerating the path for drug development.

Vikas Gupta, President of ReciBioPharm, said “Our collaboration with Hongene Biotech marks an important step forward for ReciBioPharm, enabling us to offer comprehensive, seamless solutions in the rapidly evolving gene editing sector. The combination of Hongene’s high-quality raw materials and synthesis methods with our capabilities will provide our clients with an unmatched portfolio of services in this developing field.”

Echoing the sentiment, Wei Jiang, CEO at Hongene Biotech, added “Our partnership with ReciBioPharm is set to redefine the manufacturing space for gene editing. Our cutting-edge sgRNA synthesis technology, combined with ReciBioPharm’s expertise in end-to-end mRNA and drug product manufacture, promises to bring a unique solution that has significant value to the healthcare field.”

Hongene is an end-to-end partner for specialist nucleic acid manufacturing, offering a wide range of products to meet the needs of the life sciences industry. From standard raw material building blocks to complex oligonucleotides and mRNA, Hongene consistently delivers with exceptional quality and value. Through collaborations Hongene can help unlock the full potential of nucleic acids to develop life-changing treatments for patients worldwide. For more information about Hongene and its range of nucleic acid products, visit the website www.hongene.com.

ReciBioPharm is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Led by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.